Europe resumes use of J&J COVID-19 vaccine after EMA review
Rollout of the COVID-19 vaccine from Johnson & Johnson will resume after the European Medicines Agency (EMA) confirmed that the vaccine's overall benefit-risk profile remains positive. Read More
Debiopharm launches competition for single dose COVID-19 mRNA vaccine
Debiopharm has announced a global challenge in an effort to develop a single-dose messenger RNA (mRNA) COVID-19 vaccine. Read More
Sorrento reports positive clinical results for COVID-19 stem cell treatment
Sorrento said that all 10 of the COVID-19 patients receiving its stem cell treatment in a phase IB study were discharged from the intensive care unit within three days after their last infusion. Read More
Variant-resistant COVID-19 vaccines could be effective, cheap to make
Researchers have collaborated to create a new COVID-19 vaccine platform containing antigens against the fusion protein of the SARS-CoV-2 virus that could be effective against variants of the virus. The research was published online on April 15 in the Proceedings of the National Academy of Sciences. Read More
ARMI launches new tech roadmap for pandemic response and recovery
The Advanced Regenerative Manufacturing Institute (ARMI) has released a document that outlines a technology-based plan for U.S. pandemic response and preparedness. Read More
Aegis Life starts Entos DNA COVID-19 vaccine clinical trial
Aegis Life, subsidiary of Entos Pharmaceuticals, has begun a phase I/II clinical trial of Entos' Covigenix VAX-001, a DNA COVID-19 vaccine. Read More
Adagio nabs $336M to develop COVID-19 antibody treatment/prophylactic
Adagio Therapeutics has secured $336 million that it plans to use to develop an antibody for the treatment and prevention of COVID-19. Read More
Tonix licenses SARS-CoV-2 antiviral inhibitor from OyaGen
Tonix Pharmaceuticals has agreed to obtain the exclusive worldwide license for TNX-3500 (previously OYA1), an antiviral inhibitor of SARS-CoV-2 developed by OyaGen, for the treatment of COVID-19 and potentially other viral disorders. Read More
EMA to review GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody (mAb) for the treatment of adults and adolescents 12 years old and over with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. Read More
Novavax COVID-19 vaccine to be included in combo vaccine study
Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The candidate vaccine is one of four that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter